Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
FEIBA
anti-inhibitor coagulant complex
- Restricted
- Therapeutic Interchange Miscellaneous Programs
Last updated: Apr. 29, 2026
FEIBA is the PREFERRED prothrombin complex concentrate (PCC) product for controlling and preventing bleeding episodes in patients with hemophilia A and B with inhibitors
Hemophilia Blood Factor Flow Diagram
FEIBA is the NON-PREFERRED PCC for emergent reversal of oral anticoagulants and life-threatening bleeding unresponsive to alternative therapy. FEIBA may be used when Kcentra is contraindicated due to anaphylaxis/severe reaction to heparin or proteins C or S, prior HIT, or during verified supply constraints.
Interchange orders from FEIBA to fixed-dose Kcentra unless contraindicated
Approved FEIBA prescribers:
cardiologists, cardiovasular surgeons, emergency department physicians, hematologists, medical intensivists, neurologists, neurosurgeons, vascular surgeons, and trauma surgeons.
FEIBA Diluent Volumes:
500 unit vial = 10 mL
1,000 unit vial = 20 mL
2,500 unit vial = 50 mL
Round dose to nearest vial size.
Reviewed: 28 Aug 2018 (FEIBA)
Updated: November 2025 Kcentra Formulary Update (2) (3).pdf